CA
CATX.US Perspective Therapeutics Inc.
- Market cap
- USD 114M
- P/E
- -
- P/B
- 0.35x
- ROE
- -38.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CATX.US undervalued?
Graham numberThe Graham number of Perspective Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Perspective Therapeutics Inc. fundamental analysis
No fundamental analysis for Perspective Therapeutics Inc. yet.
Perspective Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, s…
Full company profilePerspective Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Perspective Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.77M | 4.76M | 7.31M | 9.68M | 10.1M | 10.8M | 5.42M | 1.43M | 1.45M | 884K | 236K |
| Gross Profit | 129K | 838K | 3.05M | 5.12M | 5.12M | 4.62M | 2.37M | 1.43M | -852K | -2.37M | -1.27M |
| Operating Income | -5.08M | -6.31M | -5.28M | -3.48M | -3.44M | -7.39M | -9.10M | -40.9M | -66.8M | -114M | -122M |
| EBITDA | 471K | -6.19M | -5.14M | -3.48M | -3.29M | -7.14M | -8.47M | -40.0M | -64.5M | -101M | -112M |
| Net Income | -4.71M | -6.16M | -4.85M | -3.27M | -3.19M | -7.27M | -10.8M | -46.5M | -79.3M | -103M | -114M |
| EPS | -0.09 | -0.11 | -0.07 | -0.05 | -0.06 | -0.51 | -0.76 | -0.85 | -1.23 | -1.40 | -0.94 |
| Balance Sheet | |||||||||||
| Total Assets | 18.1M | 12.3M | 9.42M | 8.70M | 15.5M | 64.4M | 58.1M | 97.9M | 341M | 267M | 366M |
| Total Liabilities | 1.70M | 1.67M | 1.74M | 2.98M | 2.74M | 3.16M | 3.45M | 22.7M | 50.4M | 59.9M | 71.0M |
| Shareholders' Equity | 16.4M | 10.6M | 7.68M | 5.72M | 12.8M | 61.3M | 54.6M | 75.2M | 291M | 207M | 295M |
| Cash & Short-term Investments | 12.4M | 8.97M | 5.33M | 2.39M | 9.59M | 55.9M | 43.8M | 9.24M | 227M | 145M | 202M |
| Total Debt | - | - | - | 1.01M | 897K | - | 524K | 2.55M | 4.06M | 3.25M | 3.62M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.88M | -5.71M | -5.05M | -3.64M | -2.84M | -7.71M | -7.71M | -36.9M | -18.3M | -82.5M | -111M |
| Capital Expenditure | 479K | 549K | 444K | 273K | 381K | 266K | 266K | 1.07M | 54.4M | 12.7M | 34.1M |
| Free Cash Flow | -4.36M | -6.26M | -5.49M | -3.91M | -3.22M | -7.98M | -7.98M | -38.0M | -72.7M | -95.2M | -145M |
| Ratios | |||||||||||
| ROE | -28.7% | -58.1% | -63.2% | -57.1% | -25.0% | -11.9% | -19.7% | -61.9% | -27.3% | -49.8% | -38.6% |
| ROA | -26.0% | -50.2% | -51.5% | -37.6% | -20.6% | -11.3% | -18.5% | -47.5% | -23.2% | -38.6% | -31.1% |
| Net Profit Margin | -98.8% | -129.4% | -66.3% | -33.8% | -31.7% | -67.4% | -198.7% | -3,243.2% | -5,452.5% | -11,665.3% | -48,258.2% |
| Debt to Equity | - | - | - | 0.18x | 0.07x | - | 0.01x | 0.03x | 0.01x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Perspective Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 9.00K | 0.00 | - |
| 2019 | USD 11.0K | 0.00 | - |
| 2018 | USD 11.0K | 0.00 | - |
| 2017 | USD 11.0K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jun 17, 2024.
Who owns Perspective Therapeutics Inc.
- Insiders 7.82%
- Institutions 79.19%
- Public & others 13.00%
- Shares outstanding 121M
- Free float 77.4M
Perspective Therapeutics Inc. company profile
- Company name
- Perspective Therapeutics Inc.
- Ticker
- CATX.US
- Exchange
- USA Stocks
- Listed since
- Nov 10, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 163
- Fiscal year end
- December
- Address
- 2401 Elliott Avenue, Seattle, WA, United States, 98121
- Phone
- 206 676 0900
- Website
- perspectivetherapeutics.com
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics Inc. management
10- Mr. Johan M. SpoorCEO & Director · born 1972
- Mr. Joel David SendekCFO & Principal Financial Officer · born 1967
- Dr. Markus Puhlmann M.B.A., M.D.Chief Medical Officer · born 1966
- Dr. Michael K. Schultz Ph.D.Co-Founder & Senior Scientific Advisor
- Mr. Shane CobbExecutive Vice President of Operations
- Mr. Jonathan R. HuntChief Accounting Officer · born 1967
- Dr. Paul Lyne Ph.D.Chief Science Officer
- Ms. Annie J. ChengVice President of Investor Relations · born 1976
- Mr. Chris NennoGeneral Counsel & Corporate Secretary
- Mr. Andrew BrightExecutive Vice President of Brachytherapy